



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number:

**0 421 635 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 19.07.95 (61) Int. Cl.<sup>8</sup>: A61K 39/295, C12N 15/62

(21) Application number: 90310264.8

(22) Date of filing: 19.09.90

(54) Chimaeric hepatitis virus core antigen proteins.

(30) Priority: 19.09.89 GB 8921172  
13.08.90 GB 9017728

(43) Date of publication of application:  
10.04.91 Bulletin 91/15

(45) Publication of the grant of the patent:  
19.07.95 Bulletin 95/29

(64) Designated Contracting States:  
BE CH DE DK ES FR GB IT LI NL SE

(56) References cited:  
US-A- 4 859 465

NATURE, vol. 330, no. 6146, 26th November -  
2nd December 1987, pages 381-384, London,  
GB; B.E. CLARKE et al.: "Improved Im-  
munogenicity of a peptide epitope after fu-  
sion to hepatitis B core protein"

THE EMBO JOURNAL, vol. 7, no. 3, 1988,  
pages 819-824, IRL Press Ltd, Oxford, GB; P.  
ARGOS et al.: "A model for the hepatitis B  
virus core protein: prediction of antigenic  
sites and relationship to RNA virus capsid  
proteins"

(73) Proprietor: THE WELLCOME FOUNDATION  
LIMITED  
Unicorn House  
160 Euston Road  
London NW1 2BP (GB)

(72) Inventor: Brown, Alan Louis  
c/o The Wellcome Foundation Ltd.,  
Langley Court  
Beckenham,  
Kent BR3 3BS (GB)  
Inventor: Clarke, Berwyn Ewart  
c/o The Wellcome Foundation Ltd.,  
Langley Court  
Beckenham,  
Kent BR3 3BS (GB)  
Inventor: Rowlands, David John  
c/o The Wellcome Foundation Ltd.,  
Langley Court  
Beckenham,  
Kent BR3 3BS (GB)

(74) Representative: Stott, Michael John et al  
The Wellcome Foundation Limited  
Group Patents & Agreements  
Langley Court  
Beckenham  
Kent BR3 3BS (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 421 635 B1

PROC. NATL. ACAD. SCI. USA, vol. 86, August 1989, pages 6283-6287; S.J. STAHL et al.: "Immunogenicity of peptide fusions to hepatitis B virus core antigen"

---

## Description

This invention relates to the construction of chimaeric hepadnavirus core antigen proteins.

Hepatitis B virus is a hepadnavirus virus with a partly double stranded genome of 3200 nucleotides. The viral DNA is surrounded by the viral coded core antigen (HBcAg) which is enclosed by the similarly coded surface antigen (Robinson, *Ann. Rev. Microbiol.* **31**, 357-377, 1977). Removal of the surface antigen by mild detergent treatment leaves a core particle 27nm in diameter composed of HBcAg and the viral DNA. HBcAg has been expressed in microbial cells as the native polypeptide and as a derivative fused to the terminal eight residues of beta-galactosidase (see Murray *et al*, *EMBO J.* **3**, 645-650, 1984 for refs).

When synthesized in *E. coli* the core protein self assembles into 27nm particles which can be visualized under the electron microscope (Cohen and Richmond, *Nature*, **296**, 677-678, 1982) and which are immunogenic in laboratory animals (Stahl *et al*, *Proc. Natl. Acad. Sci. USA* **79**, 1606-1610, 1982). The amino acid sequence of the core antigen shows a region towards the carboxy terminus which is homologous with that found in protamines (DNA binding proteins). By inference, it has been suggested that this part of the molecule interacts with DNA during assembly of core particles (Pasek *et al*, *Nature*, **282**, 575-579, 1979).

The use of recombinant particles comprising hepatitis B core antigen and heterologous protein sequences as potent immunogenic moieties is well documented. We have previously shown that addition of heterologous sequences to the amino terminus of the protein results in the spontaneous assembly of particulate structures on the surface of which the heterologous epitope is presented at high density and which are highly immunogenic when inoculated into experimental animals (Clarke *et al*, *Nature* **330**, 381-384, 1987). Similar results have been reported by other groups using our system (e.g. Chang *et al*, 2nd International Symposium on positive strand RNA viruses, Vienna, Austria, 1989, abstract 010).

Subsequent experiments by other groups have shown that it is also possible to replace approximately 40 amino acids from the carboxy terminus of the protein with heterologous sequences and still maintain particle morphogenesis (Stahl & Murray, *Proc. Natl. Acad. Sci. USA*, **86** 6283-6287, 1989). Moreover these particles are also immunogenic although, apparently, less so than the amino terminal fusions.

Despite the fact that these fusion particles induce excellent immune responses against the added epitope there still remains room for improvement from several points of view. Firstly, the immune responses against the added epitope, although excellent, do not compare with the parallel responses generated against the HBcAg sequences. Secondly, in both the amino and carboxy terminal fusions the added epitope possesses inherent flexibility because it is only covalently bound at one end. This may be disadvantageous for conformationally rigid epitopes. Thirdly, a model of the structure of hepatitis B core antigen has predicted that, naturally, both the amino and carboxy termini of the protein are located internally within the particles (Argos & Fuller, *EMBO J.* **1**, 819-824, 1988). It is only the inherently hydrophilic nature of most of the heterologous epitopes which directs them to the surface.

We have now located a region of high immunogenicity in a surface region of HBcAg particles. A vector encoding HBcAg and having a restriction site in this region of high immunogenicity has been constructed. Foreign sequences have been inserted at the restriction site, enabling chimaeric HBcAg proteins to be expressed. The chimaeric proteins self-assemble into particles having a foreign epitope exposed on their surface.

Accordingly, the present invention provides particles composed of a chimaeric hepadnavirus core protein having a foreign amino acid sequence comprising an epitope inserted in or replacing all or part of the amino acid sequence from residue 75 to residue 85 in the case where the core antigen is HBcAg or the corresponding amino acid sequence in the case of another hepadnavirus core antigen. HBcAg residues are numbered according to Ono *et al*, *Nucl. Acid. Res.* **11**, 1747-1757, 1983. Corresponding residues of the core protein of another hepadnavirus may be determined by lining up the sequences of HBcAg and the other core protein.

The chimaeric protein particles can be used to raise antibody specific for the epitope carried by the chimaeric protein. Antibody can therefore be raised in a mammal by administering to the mammal an effective amount of the particles composed of the chimaeric protein wherein the foreign sequence comprises an epitope capable of inducing antibody of the desired specificity. The chimaeric protein particles may be presented for this purpose as a component of a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent.

The invention also provides an expression vector which comprises a DNA sequence encoding a hepadnavirus core protein and having (a) a restriction site within the sequence encoding HBcAg amino acid residues 75 to 85 or the corresponding sequence of the core protein of another hepadnavirus or (b) two restriction sites flanking a said sequence or a part of a said sequence encoding HBcAg amino acid residues 68 to 90 or the corresponding sequence of the core protein of another hepadnavirus. Where HBcAg codons

75 to 85 or their counterpart codons for the core protein of another hepadnavirus have been deleted completely or in part, the restriction site is located appropriately in the sequence remaining. Where two restriction sites are provided, typically they are cut by the same restriction enzyme.

Such an expression vector can be provided in a host. The vector provides a starting point for the preparation of a vector capable of expressing the chimaeric protein of the invention. For this purpose, a DNA sequence needs to be constructed which encodes the chimaeric protein. More particularly, a vector is required which incorporates such a DNA sequence and which is capable, when provided in a suitable host, of expressing the chimaeric protein.

A vector capable of expressing the chimaeric protein is prepared by inserting a DNA sequence encoding the foreign sequence into a vector which encodes a hepadnavirus core protein and which has a restriction site or sites (a) or (b) as above. Preferably a restriction site (a) occurs at HBcAg codons 80 and 81 or at the corresponding codons for the core protein of another hepadnavirus. The resulting vector encoding the chimaeric protein is typically provided in a compatible host.

To obtain the chimaeric protein, a host is cultured under such conditions that the chimaeric protein is expressed. The host is provided with an expression vector encoding the chimaeric protein. The chimaeric protein self-assembles into particles when expressed, and can then be isolated. These particles closely resemble the 27 nm core particles composed of HBcAg and viral DNA which can be obtained by denaturing hepatitis B virus. The foreign epitope is exposed on the outer particle surface.

The chimaeric protein comprises a foreign amino acid sequence comprising an epitope. By "foreign" is meant that the sequence is not part of the sequence of the hepadnavirus core protein. The foreign sequence inserted into or replacing all or part of HBcAg amino acid residues 75 to 85 is not therefore part or all of the insert of 39 amino acids near the predicted position of the HBe1 epitope of avian hepatitis viruses, in particular of viruses from ducks (Feitelson and Miller, Proc. Natl. Acad. Sci. USA, 85, 6162-6166, 1988). The hepadnavirus core protein portion of the chimaeric protein is typically a mammalian hepadnavirus core antigen, in particular the human HBcAg or woodchuck WHcAg. Hepatitis B virus adw serotype HBcAg may be used.

Any foreign epitope, i.e. an epitope which is not an epitope of a hepadnavirus core protein, can be presented as part of the chimaeric protein. The epitope is a sequence of amino acid residues capable of raising antibody. The epitope may be an epitope capable of raising neutralising antibody, for example an epitope of an infectious agent or pathogen such as a virus or bacterium. It may be an epitope of a non-infectious agent such as a growth hormone. The foreign sequence may comprise repeats of an epitope, for example up to eight or up to four copies of an epitope. Two copies of an epitope may therefore be present in the foreign sequence. A foreign sequence may comprise two or more different epitopes, for example three or four.

As examples of viruses whose epitopes may be presented there may be mentioned hepatitis A virus, hepatitis B virus, influenza virus, foot-and-mouth disease virus, poliovirus (PV), herpes simplex virus, rabies virus, feline leukaemia virus, human immunodeficiency virus type 1 (HIV-1), HIV-2, simian immunodeficiency virus (SIV), human rhinovirus (HRV), dengue virus and yellow fever virus. The epitope presented by the chimaeric protein may be therefore an epitope of HBsAg, of the pre-S region of HBsAg or of HRV2.

The foreign sequence in the chimaeric protein may be up to 100, for example up to 50, amino acid residues long. The foreign sequence may therefore be up to 40, up to 30, up to 20 or up to 10 amino acid residues in length. The foreign sequence comprises the epitope against which it is desired to induce antibody. The foreign sequence may also comprise further amino acid residues at either or both ends of the epitope.

Where further amino acid residues are present, these may be determined by the manipulations necessary to insert DNA encoding a desired foreign epitope into a vector encoding a hepadnavirus core antigen. They may be the amino acids which naturally flank the epitope. Up to 10, for example up to 4, further amino acids may be provided at either or each end of the foreign epitope.

The foreign sequence is inserted in the sequence of HBcAg residues from 75 to 85 or corresponding residues of another hepadnavirus core protein. Most preferred is to insert the foreign sequence between HBcAg amino acid residues 80 and 81 or between the corresponding residues of another hepadnavirus core protein. Alternatively, all or part of the sequence of core protein residues may be replaced by the foreign sequence. HBcAg amino acid residues 75 to 85 or 80 and 81 or corresponding residues of another hepadnavirus core protein may therefore be replaced by the foreign sequence. Where a foreign sequence replaces all or part of the native core protein sequence, the inserted foreign sequence is generally not shorter than the HBcAg sequence it replaces.

A second foreign amino acid sequence may be fused to the N-terminus or C-terminus of the amino acid sequence of the core protein. This second foreign sequence may also comprise an epitope. This epitope may be identical to or different from the epitope inserted into or replacing all or part of HBcAg amino acid residues 75 to 85 or the corresponding residues of the core protein of another hepadnavirus (the first epitope). Any foreign epitope may be present as the second epitope, as described above in connection with the first epitope. The length and construction of the foreign sequence containing the second epitope may also be as described above in connection with the first epitope.

In order to prepare the chimaeric protein, an expression vector is first constructed. Thus a DNA sequence encoding the desired chimaeric protein is provided. An expression vector is prepared which incorporates the DNA sequence and which is capable of expressing the chimaeric protein when provided in a suitable host. Appropriate transcriptional and translational control elements are provided, including a promoter for the DNA sequence, a transcriptional terminal site, and translational start and stop codons. The DNA sequence is provided in the correct frame such as to enable expression of the polypeptide to occur in a host compatible with the vector.

An appropriate vector capable of expressing the chimaeric protein may be constructed from an HBcAg expression vector having a restriction site (a) or two restriction sites (b) as above.

A DNA sequence encoding the foreign amino acid sequence is inserted into the HBcAg expression vector at the restriction site (a) or in place of the DNA sequence flanked by restriction sites (b). The HBcAg expression vector is digested with the appropriate restriction endonuclease(s) and dephosphorylated. The DNA sequence encoding the foreign sequence is ligated into the cut expression vector. The inserted DNA sequence is typically prepared by standard techniques of oligonucleotide synthesis.

A or each restriction site in the HBcAg expression vector is preferably provided in the HBcAg coding sequence such that the HBcAg amino acid sequence is not altered. A restriction site (a) may occur at HBcAg codons 80 and 81 or the counterpart codons for another hepadnavirus core protein. Preferably, a NheI site is provided in the HBcAg coding sequence at codons 80 and 81. *E. coli* XL-1 Blue harbouring plasmid pPV-Nhe, which is an HBcAg expression vector provided with such a NheI site, was deposited at the National Collection of Industrial and Marine Bacteria, Aberdeen, GB on 12 September 1989 under accession number NCIMB 40210.

Introduction of a novel restriction site can be achieved in either of two ways. First it may be achieved by replacement of a small restriction fragment coding for this region by a series of synthetic oligonucleotides coding for this region and incorporating the novel restriction site (see Example 1).

Secondly it may be achieved by site directed mutagenesis of the same coding region. This may typically be carried out by initially sub-cloning a restriction fragment representing this region into a vector such as M13mp18 which can produce single stranded DNA. Site directed mutagenesis may then be achieved using specific mismatched synthetic oligonucleotides by standard methods. Such a mutated restriction fragment can then be replaced into the parent gene in a suitable expression vector.

The expression vectors encoding a chimaeric protein are provided in an appropriate host. The chimaeric protein is then expressed. Cells harbouring the vector are grown/cultured so as to enable expression to occur. The chimaeric protein that is expressed self-assembles into particles. The chimaeric particles may then be isolated.

Thus the invention also provides:

- a host transformed with a vector which comprises DNA sequence encoding a chimaeric protein in accordance with the invention, so that the chimaeric protein is able to be expressed therein;
- a process for the preparation of such a host, which comprises transforming a host with a compatible expression vector which comprises a DNA sequence encoding a chimaeric protein in accordance with the invention; and
- a process for the preparation of chimaeric protein particles according to the invention, which comprises culturing a transformed host of the invention under such conditions that the chimaeric protein is expressed therein and recovering particles composed of the chimaeric protein which thus form.

Any appropriate host-vector system may be employed. The vector may be plasmid. In that event, a bacterial or yeast host may be used for example *E. coli* or *S. cerevisiae*. Alternatively, the vector may be a viral vector. This may be used to transfect cells of a mammalian cell line, such as Chinese hamster ovary (CHO) cells, in order to cause polypeptide expression.

The chimaeric protein may be used as a vaccine for a human or animal. It may be administered in any appropriate fashion. The choice of whether an oral route or a parenteral route such as sub-cutaneous, intravenous or intramuscular administration is adopted and of the dose depends upon the purpose of the vaccination and whether it is a human or mammal being vaccinated. Similar criteria govern the physiologi-

cally acceptable carrier or diluent employed in the vaccine preparation. Conventional formulations, carriers or diluents may be used. Typically, however, the fusion protein is administered in an amount of 1-1000 µg per dose, more preferably from 10-100 µg per dose, by either the oral or the parenteral route.

The following Examples illustrate the invention. In the accompanying drawings:

- 5 Figure 1 shows plasmid pBc404. B, E and P denote restriction sites for BamHI, EcoRI and PstI respectively; tac denotes the tac promoter; ori denotes the origin of replication; bla denotes β-lactamase and SD denotes the Shine-Dalgarno sequence.

Figure 2 shows the construction of plasmid pPV-Nhe.

- 10 Reference Example: Preparation of HBcAg provided at its N-terminus with a short extension comprising PV1 Mahoney VP1 residues 95 to 104

- An expression plasmid pPV404 was prepared from the parent plasmid pBc404 shown in Figure 1. E. coli JM101 harbouring pBc404 was deposited at the National Collection of Industrial and Marine Bacteria, 15 Aberdeen, GB on 9 February 1989 under accession number NCIMB 40111. Synthetic oligonucleotides representing amino acids 95 to 104 of VP1 from PV1 Mahoney were ligated into pBc404 using T4 ligase by standard procedures. This resulted in pPV404. The synthetic oligonucleotides, how they anneal together and the coding sequence of the N-terminal extension are as follows:

20

1. AATTCAGATAATCCAGCTAGTACTACCAACAAAGATAAG (39)

2. GATCCTTATCTTTGTTGGTAGTACTAGCTGGATTATCTG (39)

25

AATTCAG ATAATCCAGC TAGTACTACC AACAAAGATA AG

GTC TATTAGGTCG ATCATGATGG TTGTTTCTAT TCCTAGG

30

10 20 30 40

35

ATGAATTCAGATAATCCAGCTAGTACTACCAACAAAGATAAGGATCC.....CORE

M N S D N P A S T T N K D K D

40

LINKER

POLIOVIRUS

- 45 Example 1: Preparation of plasmid pPV-Nhe

- A series of peptides 20 amino acids in length were chemically synthesised. These peptides overlapped each other by 10 amino acids and together represented the whole amino acid sequence of the core protein from hepatitis B virus and serotype. Each of these peptides was used to coat microtitre plates in carbonate 50 coating buffer and was used in an enzyme-linked immunosorbent assay (ELISA) analysis with sera from guinea pigs. The guinea pigs had been inoculated with bacterially-expressed hepatitis B core particles.

- One of the peptides, corresponding to amino acids 71 to 90, gave an extremely powerful reaction. This indicated that core particles had elicited antibodies in vivo which reacted with the linear peptide sequence. The sequence corresponded roughly to the reported HBs1 epitope of hepatitis B core particles (Williams and LeBouvier, Biblitheca Haematologica 42, 71-75, 1976). Our results suggested that the insertion into or 55 replacement of this immunodominant region of HBcAg by a foreign epitope may result in a chimaeric protein displaying enhanced immunogenicity with regard to the foreign epitope. We therefore undertook to insert foreign sequences into the adw core sequ nc .

The strategy which we followed is shown in Figure 2. The initial plasmid was plasmid pPV404. This plasmid expresses large amounts of chimaeric particles in bacteria which are highly immunogenic in animals. The strategy involved the introduction of a unique NheI restriction site at amino acid positions 80-81 in the core gene. This does not result in an amino acid change in the core protein. The nature of the mutation is shown below:

Amino acid	L	E	D	P	A	S	R	D	L
adw	TTG	GAA	GAT	CCA	GCA	TCC	AGG	GAT	CTA
adw-NheI	TTG	GAA	GAT	CCA	<u>GCT AGC</u>	AGG	GAT	CTA	
	NheI								

Initially plasmid pPV404 was digested with restriction enzymes XbaI and AccIII resulting in two fragments of 3.96 kbp and 340 bp. These fragments were separated by electrophoresis on low melting point agarose, excised and the smaller fragment was then further digested with XhoI resulting in 3 fragments as shown in Figure 2.

Concomitantly two oligonucleotides were synthesised with sequences as shown in Figure 2. These oligonucleotides were annealed and phosphorylated by standard procedures such that they represented a linker sequence with XhoI compatible "sticky ends" and an internal NheI site. These oligonucleotides were then ligated into the 340 bp fragment by standard procedures to replace the 19 bp natural XhoI fragment. This ligated material was then ligated back into the large 3.96 kbp fragment and transformed into *E. coli* strain XL-1 Blue by standard methods.

The design of this strategy did not exclude the possibility of the natural 19 bp XhoI fragment reinserting itself into the vector. To select for bacteria harbouring plasmids containing the new NheI site, a culture was prepared from all the recombinant clones generated during the transformation. This culture was then used to extract plasmid DNA representing the whole "library" of colonies. After caesium chloride purification this DNA was digested with NheI.

Only those recombinant plasmids carrying the new linker would have been digested in this way resulting in linearisation of this population. Linear DNA was therefore purified from the rest of the undigested plasmid molecules by agarose gel electrophoresis and, after religation, was transformed back into *E. coli* to generate a pool of NheI positive transformants. Individual clones were analysed by restriction mapping. Those clones which were confirmed to have an inserted NheI site were further characterised by DNA sequencing. The restriction map of one of the resulting clones pPV-Nhe, which possessed the correct sequence, is shown in Figure 2.

As previously stated, the design of the experiment ensured the maintenance of the correct HBcAg amino acid sequence. It was not surprising therefore that expression analysis after induction with isopropyl-beta-D-thiogalactopyranoside (IPTG) confirmed the presence of a high yield of PV-HBcAg particles.

#### Example 2: Preparation of particles composed of chimaeric HBcAg proteins

The ability of pPV-Nhe to express heterologous sequences was initially assessed by insertion of epitopes from human rhinovirus type 2 (HRV2) and hepatitis B surface antigen (HBsAg). This was achieved by insertion of synthetic oligonucleotides coding for each sequence flanked by NheI cohesive ends into NheI digested and dephosphorylated pPV-Nhe. The sequences inserted at the NheI site of pPV-Nhe are shown below:

HRV2 VP2

## Epitope

5 A S V K A E T R L N P D L Q P T E C A S  
 CTAGCGTTAAAGCGGAAACGCGTTTGAACCCAGATCTGCAACCGACCGAATGCG  
 10 GCAATTCGCCTTTGCGCAAACCTTGGGTCTAGACGTTGGCTGGCTTACGCGATC

HBsAg 139-147

## Epitope

15  
 20 A S G A C T K P T D G N C A G A S  
 CTAGCGGTGCATGCACAAAACCTACTGATGGTAACTGCGCAGGTG  
 GCCACGTACGTGTTTTGGATGACTACCATTTGACGCGTCCACGATC

25 Plasmids ligated with the synthetic oligonucleotides were transformed into *E. coli* strain XL-1 Blue. Each new construct was designed so that a diagnostic internal restriction site was present allowing rapid screening of the resulting clones. The internal restriction sites were MluI for HRV2 and SphI for HBsAg. Resulting clones possessing correct restriction sites were cultured to high density in nutrient broth and  
 30 expression of chimaeric proteins was induced by addition of IPTG to the medium. Following incubation for 6 to 8 hours at 37°C bacterial cells were harvested by centrifugation, lysed by standard procedures and expressed proteins analysed by PAGE, Western blotting and ELISA. The presence of particulate structures was determined by sucrose density gradient centrifugation.

Expression of chimaeric proteins comprising either the HRV2 epitope or the HBsAg was observed. The  
 35 chimaeric proteins self-assembled into particles. Detailed expression analysis on the HRV2 epitope construct showed that expression levels were very high in bacteria, that particle formation was maintained and that the chimaeric protein reacted with anti-HRV2 sera by Western blotting. ELISA analysis also showed that the HRV2 epitope was exposed on the particle surface.

40 EXAMPLE 3: Preparation of further particulate chimaeric HBcAg proteins

Further epitopes have been inserted into pPV-Nhe. Synthetic oligonucleotides were ligated together to prepare a DNA fragment encoding the epitope and having cohesive Nhe I ends. The DNA fragment was inserted into Nhe I - digested and dephosphorylated pPV-Nhe. Plasmids ligated with the DNA fragment  
 45 were transformed into

*E. coli* strain XL-1 Blue.

Clones were cultured to high density in nutrient broth and expression of chimaeric protein was induced  
 50 by addition of IPTG to the medium. Following incubation for 6 to 8 hours at 37°C bacterial cells were harvested by centrifugation, lysed by standard procedures and expressed proteins analysed by PAGE, Western blotting and/or ELISA. The presence of particulate structures was determined by sucrose density gradient centrifugation.

Chimaeric proteins presenting the following epitopes were obtained in this way. In each case the  
 55 epitope was flanked by A-S residues due to the cloning procedure.

1. QE1-amino acid residues 15 to 47 from the Pre-S1 region of hepatitis a virus (HBV). This region is implicated in virus-cell interactions. The sequence was derived from the adw serotype.



**(a) Synthetic oligonucleotides**

```

5      |          10          20          30          40          50
      | CTAGTA ACT TAAGTGTGCC AAATCCATTA GGATTCTCTGC CAGATCATCA
      | | ATTGA ATTCACACGG TTTAGGTAAT CCTAAAGACG GTCTAGTAGT
      |-----|-----|-----|-----|-----|
10     |          60          70          80          90          100
      | GTTAGATCCA GCATTTGGAG CTAATTCGAC CAATCCAGAT TGGGACTTCA
      | CAATCTAGGT CGTAAACCTC GATTAAGCTG GTTAGGTCTA ACCCTGAAGT
      |-----|-----|-----|-----|-----|
      |          110
15     | ATCCATGTG
      | TAGGTACACG ATC

```

**(b) Coding sequence**

20

10 20 30 40 50

GCTAGTAACTTAAGTGTGCCAAATCCATTAGGATTTCTGCCAGATCATCAGTTAGAT

A S N L S V P N P L G F L P D H Q L D

25

CCAGCATTGGAGCTAATTCGACCAATCCAGATTGGGACTTCAATCCATGTGCTAG

P A F G A N S T N P D W D F N P C A S

2. QM2-133-144 from Pre-S2 region of HBV. This region is a sequential epitope in HBV and can protect chimpanzees from infection. The sequence was derived from the adw serotype.

(a) Synthetic oligonucleotides

```

35      10      20      30      40
      CTAGTGATC CGCGCGTGCG CGGCTTATAC TTACCGGCGG GAG
      ACTAG GCGCGCACGC GCCGAATATG AATGGCCGCC CTCGATC
40

```

**(b) Coding sequence**

45

10 20 30 40

GCTAGTGATCCGCGCGTGCGGGCTTATACTTACCGGCGGGAGCTAGC

A S D P R V R G L Y L P A G A S

3. QE2-120-153 from Pre-S2 region of HBV. This is a larger version of 2. The sequence was derived from the adw serotype.

## (a) Synthetic oligonucleotides

5                   10                   20                   30                   40                   50  
 CTAGCATGC AATGGAATAG CACCGCGTTA CACCAAGCTT TGCAGGACCC  
           GTACG TTACCTTACT GTGGCGCAAT GTGGTTCGAA ACGTCCTGGG  
 10                   60                   70                   80                   90                   100  
 TCGAGTACGT GGCTTATACT TACCGGCGGG AGGATCAAGC AGCGGCACCG  
 AGCTCATGCA CCGAATATGA ATGGCCGCCC TCCTAGTTCG TCGCCGTGGC  
 15                   110  
 TTAATCCGG  
 AATTAGGCCG ATC

## 20 (b) Coding sequence

25                   10                   20                   30                   40                   50  
 GCTAGCATGCAATGGAATAGCACCGGTTACACCAAGCTTTGCAGGACCCTCGAGT  
           A S M Q W N S T A L H Q A L Q D P R V  
 30                   60                   70                   80                   90                   100  
 ACGTGGCTTATACTTACCGGCGGGAGGATCAAGCAGCGGCACCGTTAATCC  
           R G L Y L P A G G S S S G T V N P  
 35                   110  
 GGCTAGC  
           A S

## 35 4. pPD1-110-148, a couplex epitope from HBsAg.

## (a) Synthetic oligonucleotides

40                   10                   20                   30                   40                   50  
 CTAGTATTC CTGGGTCAAC GACCACGAGC ACCGGACCAT GCAAGACGTG  
           ATAAG GACCCAGTTG CTGGTGCTCG TGGCCTGGTA CGTTCTGCAC  
 45                   60                   70                   80                   90                   100  
 TACTACACCA GCACAAGGTA ACTCCAAGTT CCCGAGCTGC TGCTGCACAA  
 ATGATGTGGT CGTGTTCCAT TGAGGTTCAA GGGCTCGACG ACGACGTGTT  
 50                   110                   120  
 AACCTACTGA TGGTAACTGC ACTG  
 TTGGATGACT ACCATTGACG TGACGATC

55

(b) Coding sequence

5  
10  
15  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
250  
260  
270  
280  
290  
300  
310  
320  
330  
340  
350  
360  
370  
380  
390  
400  
410  
420  
430  
440  
450  
460  
470  
480  
490  
500  
510  
520  
530  
540  
550  
560  
570  
580  
590  
600  
610  
620  
630  
640  
650  
660  
670  
680  
690  
700  
710  
720  
730  
740  
750  
760  
770  
780  
790  
800  
810  
820  
830  
840  
850  
860  
870  
880  
890  
900  
910  
920  
930  
940  
950  
960  
970  
980  
990  
1000  
1010  
1020  
1030  
1040  
1050  
1060  
1070  
1080  
1090  
1100  
1110  
1120  
1130  
1140  
1150  
1160  
1170  
1180  
1190  
1200  
1210  
1220  
1230  
1240  
1250  
1260  
1270  
1280  
1290  
1300  
1310  
1320  
1330  
1340  
1350  
1360  
1370  
1380  
1390  
1400  
1410  
1420  
1430  
1440  
1450  
1460  
1470  
1480  
1490  
1500  
1510  
1520  
1530  
1540  
1550  
1560  
1570  
1580  
1590  
1600  
1610  
1620  
1630  
1640  
1650  
1660  
1670  
1680  
1690  
1700  
1710  
1720  
1730  
1740  
1750  
1760  
1770  
1780  
1790  
1800  
1810  
1820  
1830  
1840  
1850  
1860  
1870  
1880  
1890  
1900  
1910  
1920  
1930  
1940  
1950  
1960  
1970  
1980  
1990  
2000  
2010  
2020  
2030  
2040  
2050  
2060  
2070  
2080  
2090  
2100  
2110  
2120  
2130  
2140  
2150  
2160  
2170  
2180  
2190  
2200  
2210  
2220  
2230  
2240  
2250  
2260  
2270  
2280  
2290  
2300  
2310  
2320  
2330  
2340  
2350  
2360  
2370  
2380  
2390  
2400  
2410  
2420  
2430  
2440  
2450  
2460  
2470  
2480  
2490  
2500  
2510  
2520  
2530  
2540  
2550  
2560  
2570  
2580  
2590  
2600  
2610  
2620  
2630  
2640  
2650  
2660  
2670  
2680  
2690  
2700  
2710  
2720  
2730  
2740  
2750  
2760  
2770  
2780  
2790  
2800  
2810  
2820  
2830  
2840  
2850  
2860  
2870  
2880  
2890  
2900  
2910  
2920  
2930  
2940  
2950  
2960  
2970  
2980  
2990  
3000  
3010  
3020  
3030  
3040  
3050  
3060  
3070  
3080  
3090  
3100  
3110  
3120  
3130  
3140  
3150  
3160  
3170  
3180  
3190  
3200  
3210  
3220  
3230  
3240  
3250  
3260  
3270  
3280  
3290  
3300  
3310  
3320  
3330  
3340  
3350  
3360  
3370  
3380  
3390  
3400  
3410  
3420  
3430  
3440  
3450  
3460  
3470  
3480  
3490  
3500  
3510  
3520  
3530  
3540  
3550  
3560  
3570  
3580  
3590  
3600  
3610  
3620  
3630  
3640  
3650  
3660  
3670  
3680  
3690  
3700  
3710  
3720  
3730  
3740  
3750  
3760  
3770  
3780  
3790  
3800  
3810  
3820  
3830  
3840  
3850  
3860  
3870  
3880  
3890  
3900  
3910  
3920  
3930  
3940  
3950  
3960  
3970  
3980  
3990  
4000  
4010  
4020  
4030  
4040  
4050  
4060  
4070  
4080  
4090  
4100  
4110  
4120  
4130  
4140  
4150  
4160  
4170  
4180  
4190  
4200  
4210  
4220  
4230  
4240  
4250  
4260  
4270  
4280  
4290  
4300  
4310  
4320  
4330  
4340  
4350  
4360  
4370  
4380  
4390  
4400  
4410  
4420  
4430  
4440  
4450  
4460  
4470  
4480  
4490  
4500  
4510  
4520  
4530  
4540  
4550  
4560  
4570  
4580  
4590  
4600  
4610  
4620  
4630  
4640  
4650  
4660  
4670  
4680  
4690  
4700  
4710  
4720  
4730  
4740  
4750  
4760  
4770  
4780  
4790  
4800  
4810  
4820  
4830  
4840  
4850  
4860  
4870  
4880  
4890  
4900  
4910  
4920  
4930  
4940  
4950  
4960  
4970  
4980  
4990  
5000  
5010  
5020  
5030  
5040  
5050  
5060  
5070  
5080  
5090  
5100  
5110  
5120  
5130  
5140  
5150  
5160  
5170  
5180  
5190  
5200  
5210  
5220  
5230  
5240  
5250  
5260  
5270  
5280  
5290  
5300  
5310  
5320  
5330  
5340  
5350  
5360  
5370  
5380  
5390  
5400  
5410  
5420  
5430  
5440  
5450  
5460  
5470  
5480  
5490  
5500  
5510  
5520  
5530  
5540  
5550  
5560  
5570  
5580  
5590  
5600  
5610  
5620  
5630  
5640  
5650  
5660  
5670  
5680  
5690  
5700  
5710  
5720  
5730  
5740  
5750  
5760  
5770  
5780  
5790  
5800  
5810  
5820  
5830  
5840  
5850  
5860  
5870  
5880  
5890  
5900  
5910  
5920  
5930  
5940  
5950  
5960  
5970  
5980  
5990  
6000  
6010  
6020  
6030  
6040  
6050  
6060  
6070  
6080  
6090  
6100  
6110  
6120  
6130  
6140  
6150  
6160  
6170  
6180  
6190  
6200  
6210  
6220  
6230  
6240  
6250  
6260  
6270  
6280  
6290  
6300  
6310  
6320  
6330  
6340  
6350  
6360  
6370  
6380  
6390  
6400  
6410  
6420  
6430  
6440  
6450  
6460  
6470  
6480  
6490  
6500  
6510  
6520  
6530  
6540  
6550  
6560  
6570  
6580  
6590  
6600  
6610  
6620  
6630  
6640  
6650  
6660  
6670  
6680  
6690  
6700  
6710  
6720  
6730  
6740  
6750  
6760  
6770  
6780  
6790  
6800  
6810  
6820  
6830  
6840  
6850  
6860  
6870  
6880  
6890  
6900  
6910  
6920  
6930  
6940  
6950  
6960  
6970  
6980  
6990  
7000  
7010  
7020  
7030  
7040  
7050  
7060  
7070  
7080  
7090  
7100  
7110  
7120  
7130  
7140  
7150  
7160  
7170  
7180  
7190  
7200  
7210  
7220  
7230  
7240  
7250  
7260  
7270  
7280  
7290  
7300  
7310  
7320  
7330  
7340  
7350  
7360  
7370  
7380  
7390  
7400  
7410  
7420  
7430  
7440  
7450  
7460  
7470  
7480  
7490  
7500  
7510  
7520  
7530  
7540  
7550  
7560  
7570  
7580  
7590  
7600  
7610  
7620  
7630  
7640  
7650  
7660  
7670  
7680  
7690  
7700  
7710  
7720  
7730  
7740  
7750  
7760  
7770  
7780  
7790  
7800  
7810  
7820  
7830  
7840  
7850  
7860  
7870  
7880  
7890  
7900  
7910  
7920  
7930  
7940  
7950  
7960  
7970  
7980  
7990  
8000  
8010  
8020  
8030  
8040  
8050  
8060  
8070  
8080  
8090  
8100  
8110  
8120  
8130  
8140  
8150  
8160  
8170  
8180  
8190  
8200  
8210  
8220  
8230  
8240  
8250  
8260  
8270  
8280  
8290  
8300  
8310  
8320  
8330  
8340  
8350  
8360  
8370  
8380  
8390  
8400  
8410  
8420  
8430  
8440  
8450  
8460  
8470  
8480  
8490  
8500  
8510  
8520  
8530  
8540  
8550  
8560  
8570  
8580  
8590  
8600  
8610  
8620  
8630  
8640  
8650  
8660  
8670  
8680  
8690  
8700  
8710  
8720  
8730  
8740  
8750  
8760  
8770  
8780  
8790  
8800  
8810  
8820  
8830  
8840  
8850  
8860  
8870  
8880  
8890  
8900  
8910  
8920  
8930  
8940  
8950  
8960  
8970  
8980  
8990  
9000  
9010  
9020  
9030  
9040  
9050  
9060  
9070  
9080  
9090  
9100  
9110  
9120  
9130  
9140  
9150  
9160  
9170  
9180  
9190  
9200  
9210  
9220  
9230  
9240  
9250  
9260  
9270  
9280  
9290  
9300  
9310  
9320  
9330  
9340  
9350  
9360  
9370  
9380  
9390  
9400  
9410  
9420  
9430  
9440  
9450  
9460  
9470  
9480  
9490  
9500  
9510  
9520  
9530  
9540  
9550  
9560  
9570  
9580  
9590  
9600  
9610  
9620  
9630  
9640  
9650  
9660  
9670  
9680  
9690  
9700  
9710  
9720  
9730  
9740  
9750  
9760  
9770  
9780  
9790  
9800  
9810  
9820  
9830  
9840  
9850  
9860  
9870  
9880  
9890  
9900  
9910  
9920  
9930  
9940  
9950  
9960  
9970  
9980  
9990  
10000  
10010  
10020  
10030  
10040  
10050  
10060  
10070  
10080  
10090  
10100  
10110  
10120  
10130  
10140  
10150  
10160  
10170  
10180  
10190  
10200  
10210  
10220  
10230  
10240  
10250  
10260  
10270  
10280  
10290  
10300  
10310  
10320  
10330  
10340  
10350  
10360  
10370  
10380  
10390  
10400  
10410  
10420  
10430  
10440  
10450  
10460  
10470  
10480  
10490  
10500  
10510  
10520  
10530  
10540  
10550  
10560  
10570  
10580  
10590  
10600  
10610  
10620  
10630  
10640  
10650  
10660  
10670  
10680  
10690  
10700  
10710  
10720  
10730  
10740  
10750  
10760  
10770  
10780  
10790  
10800  
10810  
10820  
10830  
10840  
10850  
10860  
10870  
10880  
10890  
10900  
10910  
10920  
10930  
10940  
10950  
10960  
10970  
10980  
10990  
11000  
11010  
11020  
11030  
11040  
11050  
11060  
11070  
11080  
11090  
11100  
11110  
11120  
11130  
11140  
11150  
11160  
11170  
11180  
11190  
11200  
11210  
11220  
11230  
11240  
11250  
11260  
11270  
11280  
11290  
11300  
11310  
11320  
11330  
11340  
11350  
11360  
11370  
11380  
11390  
11400  
11410  
11420  
11430  
11440  
11450  
11460  
11470  
11480  
11490  
11500  
11510  
11520  
11530  
11540  
11550  
11560  
11570  
11580  
11590  
11600  
11610  
11620  
11630  
11640  
11650  
11660  
11670  
11680  
11690  
11700  
11710  
11720  
11730  
11740  
11750  
11760  
11770  
11780  
11790  
11800  
11810  
11820  
11830  
11840  
11850  
11860  
11870  
11880  
11890  
11900  
11910  
11920  
11930  
11940  
11950  
11960  
11970  
11980  
11990  
12000  
12010  
12020  
12030  
12040  
12050  
12060  
12070  
12080  
12090  
12100  
12110  
12120  
12130  
12140  
12150  
12160  
12170  
12180  
12190  
12200  
12210  
12220  
12230  
12240  
12250  
12260  
12270  
12280  
12290  
12300  
12310  
12320  
12330  
12340  
12350  
12360  
12370  
12380  
12390  
12400  
12410  
12420  
12430  
12440  
12450  
12460  
12470  
12480  
12490  
12500  
12510  
12520  
12530  
12540  
12550  
12560  
12570  
12580  
12590  
12600  
12610  
12620  
12630  
12640  
12650  
12660  
12670  
12680  
12690  
12700  
12710  
12720  
12730  
12740  
12750  
12760  
12770  
12780  
12790  
12800  
12810  
12820  
12830  
12840  
12850  
12860  
12870  
12880  
12890  
12900  
12910  
12920  
12930  
12940  
12950  
12960  
12970  
12980  
12990  
13000  
13010  
13020  
13030  
13040  
13050  
13060  
13070  
13080  
13090  
13100  
13110  
13120  
13130  
13140  
13150  
13160  
13170  
13180  
13190  
13200  
13210  
13220  
13230  
13240  
13250  
13260  
13270  
13280  
13290  
13300  
13310  
13320  
13330  
13340  
13350  
13360  
13370  
13380  
13390  
13400  
13410  
13420  
13430  
13440  
13450  
13460  
13470  
13480  
13490  
13500  
13510  
13520  
13530  
13540  
13550  
13560  
13570  
13580  
13590  
13600  
13610  
13620  
13630  
13640  
13650  
13660  
13670  
13680  
13690  
13700  
13710  
13720  
13730  
13740  
13750  
13760  
13770  
13780  
13790  
13800  
13810  
13820  
13830  
13840  
13850  
13860  
13870  
13880  
13890  
13900  
13910  
13920  
13930  
13940  
13950  
13960  
13970  
13980  
13990  
14000  
14010  
14020  
14030  
14040  
14050  
14060  
14070  
14080  
14090  
14100  
14110  
14120  
14130  
14140  
14150  
14160  
14170  
14180  
14190  
14200  
14210  
14220  
14230  
14240  
14250  
14260  
14270  
14280  
14290  
14300  
14310  
14320  
14330  
14340  
14350  
14360  
14370  
14380  
14390  
14400  
14410  
14420  
14430  
14440  
14450  
14460  
14470  
14480  
14490  
14500  
14510  
14520  
14530  
14540  
14550  
14560  
14570  
14580  
14590  
14600  
14610  
14620  
14630  
14640  
14650  
14660  
14670  
14680  
14690  
14700  
14710  
14720  
14730  
14740  
14750  
14760  
14770  
14780  
14790  
14800  
14810  
14820  
14830  
14840  
14850  
14860  
14870  
14880  
14890  
14900  
14910  
14920  
14930  
14940  
14950  
14960  
14970  
14980  
14990  
15000  
15010  
15020  
15030  
15040  
15050  
15060  
15070  
15080  
15090  
15100  
15110  
15120  
15130  
15140  
15150  
15160  
15170  
15180  
15190  
15200  
15210  
15220  
15230  
15240  
15250  
15260  
15270  
15280  
15290  
15300  
15310  
15320  
15330  
15340  
15350  
15360  
15370  
15380  
15390  
15400  
15410  
15420  
15430  
15440  
15450  
15460  
15470  
15480  
15490  
15500  
15510  
15520  
15530  
15540  
15550  
15560  
15570  
15580  
15590  
15600  
15610  
15620  
15630  
15640  
15650  
15660  
15670  
15680  
15690  
15700  
15710  
15720  
15730  
15740  
15750  
15760  
15770  
15780  
15790  
15800  
15810  
15820  
15830  
15840  
15850  
15860  
15870  
15880  
15890  
15900  
15910  
15920  
15930  
15940  
15950  
15960  
15970  
15980  
15990  
16000  
16010  
16020  
16030  
16040  
16050  
16060  
16070  
16080  
16090  
16100  
16110  
16120  
16130  
16140  
16150  
16160  
16170  
16180  
16190  
16200  
16210  
16220  
16230  
16240  
16250  
16260  
16270  
16280  
16290  
16300  
16310  
16320  
16330  
16340  
16350  
16360  
16370  
16380  
16390  
16400  
16410  
16420  
16430  
16440  
16450  
16460  
16470  
16480  
16490  
16500  
16510  
16520  
16530  
16540  
16550  
16560  
16570  
16580  
16590  
16600  
16610  
16620  
16630  
16640  
16650  
16660  
16670  
16680  
16690  
16700  
16710  
16720  
16730  
16740  
16750  
16760  
16770  
16780  
16790  
16800  
16810  
16820  
16830  
16840  
16850  
16860  
16870  
16880  
16890  
16900  
16910  
16920  
16930  
16940  
16950  
16960  
16970  
16980  
16990  
17000  
17010  
17020  
17030  
17040  
17050  
17060  
17070  
17080  
17090  
17100  
17110  
17120  
17130  
17140  
17150  
17160  
17170  
17180  
17190  
17200  
17210  
17220  
17230  
17240  
17250  
17260  
17270  
17280  
17290  
17300  
17310  
17320  
17330  
17340  
17350  
17360  
17370  
17380  
17390  
17400  
17410  
17420  
17430  
17440  
17450  
17460  
17470  
17480  
17490  
17500  
17510  
17520  
17530  
17540  
17550  
17560  
17570  
17580  
17590  
17600  
17610  
17620  
17630  
17640  
17650  
17660  
17670  
17680  
17690  
17700  
17710  
17720  
17730  
17740  
17750  
17760  
17770  
17780  
17790  
17800  
17810  
17820  
17830  
17840  
17850  
17860  
17870  
17880  
17890  
17900  
17910  
17920  
17930  
17940  
17950  
17960  
17970  
17980  
17990  
18000  
18010  
18020  
18030  
18040  
18050  
18060  
18070  
18080  
18090  
18100  
18110  
18120  
18130  
18140  
18150  
18160  
18170  
18180  
18190  
18200  
18210  
18220  
18230  
18240  
18250  
18260  
18270  
18280  
18290  
18300  
18310  
18320  
18330  
18340  
18350  
18360  
18370  
18380  
18390  
18400  
18410  
18420  
18430  
18440  
18450  
18460  
18470  
18480  
18490  
18500  
18510  
18520  
18530  
18540  
18550  
18560  
18570  
18580  
18590  
18600  
18610  
18620  
18630  
18640  
18650  
18660  
18670  
18680  
18690  
18700  
18710  
18720  
18730  
18740  
18750  
18760  
18770  
18780  
18790  
18800  
18810  
18820  
18830  
18840  
18850  
18860  
18870  
18880  
18890  
18900  
18910  
18920  
18930  
18940  
18950  
18960  
18970  
18980  
18990  
19000  
19010  
19020  
19030  
19040  
19050  
19060  
19070  
19080  
19090  
19100  
19110  
19120  
19130  
19140

## (a) Synthetic oligonucleotides

475 466 476  
 5 CTAGCGCAGCACAAATTTCCCTTCAATGCAAGCGATTGAGTCGGACAACAGATAAAG  
 GCGTCGTGTTAAAGGGAAGTTACGTTGCTAAGTCAGCCTGTTGTCTATTTTC  
 478 469 477  
 10 GTTATACCTGTGGATCCTG  
 CAATATGGACACCTAGGACGATC

## (b) Coding sequence

10 20 30 40 50  
 GCTAGCGCAGCACAAATTTCCCTTCAATGCAAGCGATTGAGTCGGACAACAGATAAA  
 20 A S A A Q F P F N A S D S V G Q Q I K  
 60 70 80  
 GGTATACCTGTGGATCCTGCTAGC  
 V I P V D P A S

## 8. pPA4-VP1 160-182 HAV

## (a) Synthetic oligonucleotides

491 492 493  
 30 CTAGCACACCTGTTGGACTAGCAGTAGATACTCCCTGGGTTGAGAAAGAGTCAGCA  
 GTGTGGACAACCTGATCGTCATCTATGAGGGACCCAACCTCTTCTCAGTCGT  
 496 495 494  
 35 CTATCGATTGACTATG  
 GATAGCTAACTGATACGATC

## (b) Coding sequence

10 20 30 40 50  
 45 GCTAGCACACCTGTTGGACTAGCAGTAGATACTCCCTGGGTTGAGAAAGAGTCA  
A S T P V G L A V D T P W V E K E S  
 60 70  
 GCACTATCGATTGACTATGCTAGC  
 50 A L S I D Y A S

## 9. pPA5-VP2 40-60 HAV

## 5

10

## 15

20

25

## 30

35

## 40

45

50

## 55

13

60 70 80  
 AGATCAAAAG CCACCAAGTC GTCAAG  
 TGTAGTTTTC GGTGGTTCAG CAGTTCGATC

b) coding sequence

10 20 30 40  
 GCTAGTACTATCACTCCACCACAGGCCATGGGTCCAAACTTA  
 A S T I T P P Q A M G P N L  
 50 60 70 80  
 GTCTTACCAGATCAAAAGCCACCAAGTCGTCAAGCTAGC  
 V L P D Q K P P S R Q A S

Example 4: Preparation of chimaeric protein having a HRV2 epitope at both the amino terminus and inserted between HBcAg residues 80 and 81

Oligonucleotides coding for the HRV2 VP2 epitope shown in Example 2 were inserted into the pPV-Nhe vector as specified in that Example. The recombinant vector was digested with EcoRI and BamHI. A band of approximately 4.4kb was purified by low melting point agarose gel electrophoresis. Synthetic oligonucleotides representing amino acids 158 to 170 of VP2 from HRV2 were ligated into the recombinant vector using T4 ligase by standard procedures. The synthetic oligonucleotides, how they anneal together and the coding sequence of the N-terminal extension were as follows:

1. AATTCAGTTAAAGCGGAAACGCGTTTG

2. AACCCAGATCTGCAACCGACCGAATGCCGG

3. GATCCCGGCATTGGTTCGGTTGCA

4. GATCTGGGTTCAAACGCGTTTCCGCTTTAACTG

AATTCAGTTAAAGCGGAAACGCGTTTGAACCCAGATCTGCAACCGACCGAATGCCGG  
 GTCAATTTCCGCTTTGCGCAAACCTGGGTCTAGACGTTGGCTGGCTTACGGCCTAG

30  
 ATG AAT TCA GTT AAA GCG GAA ACG CGT TTG AAC CCA GAT CTG CAA  
 M N S V K A E T R L N P D L Q  
 LINKER HRV2

60  
 CCG ACC GAA TGC CGG GAT CC  
 P T E C R D

The resulting plasmid was transformed into *E. coli* strain XL-1 Blue. Clones were cultured to high density in nutrient broth. Expression of chimaeric protein was achieved as described in Example 2. Expressed proteins were analysed by PAGE, Western blotting and ELISA. The presence of particulate structures was determined by sucrose density gradient centrifugation.

#### Example 5: Animal tests

##### Immunisation protocol

Female Dunkin Hartley guinea-pigs weighing about 400g were each inoculated intramuscularly with a 0.5 ml dose of a chimaeric HBcAg protein preparation formulated in incomplete Freund's adjuvant (IFA).

Groups of four animals were inoculated with a specified dose of purified core particles and boosted once at either 56 or 70 days with the same initial dose. Blood samples were taken at 14 day intervals throughout the experiment.

## 5 ELISA

Antipeptide, antiviral and anti-particle activity in serum samples was measured by a modification of an indirect or double antibody sandwich ELISA method. In the sandwich ELISA polyclonal antipeptide serum (1:200) was used to capture serial dilutions of particles in PBS and 2% dried milk powder. In the indirect  
 10 ELISA 2 µg/ml of peptide, particle or virus were coated directly onto microtitre plates. In each case the plates were washed and incubated with test serum samples. Following incubation at 37°C for 1-2 hours plates were rewashed and anti-IgG-peroxidase conjugate was added. After a further hour at 37°C the plates were washed and an enzyme substrate (0.04% o-phenylenediamine and 0.004% hydrogen peroxide in 0.1M phosphate 0.05M citrate buffer) was added. The resulting colour development was stopped with sulphuric  
 15 acid and the A492 was measured in a Titertek Multiskan (Trade Mark, Flow Labs).

The A492 values obtained from dilutions of post-inoculation samples were plotted against the log10 reciprocal antiserum dilution and the antibody titre was calculated by reference to a negative standard (a 1:10 dilution of pre-inoculation serum).

## 20 Results

1. Guinea pigs were inoculated intramuscularly with 20 µg or 2 µg of particles obtained in Example 3.1 composed of the PreS1-HBcAg chimaeric protein. Bleeds were taken at regular intervals. In each case a peptide composed of the PreS1 insert in the chimaeric HBcAg protein (392), HBcAg with no insert  
 25 (control) and PreS1-HBcAg particles were coated onto enzyme-linked immunosorbent assay (ELISA) dishes and then assayed against dilutions of the antisera collected. The results are shown in Table 1. Very high levels of antipeptide, antiHBcAg and antiPreS1-HBcAg particles antibody were achieved.

2. The procedure was the same as in 1 except:

- guinea pigs were inoculated with particles obtained in Example 3.2 composed of the small PreS2 epitope-HBcAg chimaeric protein;
- a peptide composed of the PreS2 insert (393), HBcAg, PreS2-HBcAg particles and yeast-derived HBsAg particles with PreS2 epitopes incorporated were coated onto ELISA dishes.

The results are shown in Table 2. Very high levels of antibody were again induced in the guinea pigs.

3. The immune responses induced in guinea pigs and rabbits by particles composed of a chimaeric HBcAg protein in which a HRV2 VP2 epitope is inserted in accordance with the invention ("insert", Example 2) and by particles composed of a chimaeric HBcAg protein in which the same HRV2 VP2 epitope is fused to the amino terminus of HBcAg ("terminal") were compared. The "terminal" chimaeric HBcAg protein was prepared in accordance with the procedure described in JP-A-196299/88. The results  
 40 are shown in Tables 3 and 4 and are ELISA endpoint titres (log<sub>10</sub>). The ELISA plates were coated with either a peptide composed of the HRV2 VP2 epitope or HBV. The "insert" chimaeric HBcAg protein gave superior results: higher anti-HRV peptide titres and lower anti-HBV titres.

4. The neutralising antibody responses were looked at of the guinea pigs and rabbits of 3. above. In particular, the responses of the animals to two inoculations of the "insert" particles were assayed. The results are shown in Table 5.

5. Rabbits and guinea pigs were inoculated intramuscularly with particles composed of the chimaeric HBsAg 139-147 epitope-HBcAg protein of Example 2. Anti-peptide 139-147 (α pep 448) and anti-HBsAg (αHBsAg) responses were determined using three doses of particles. The results are shown in Table 6. The data shown are titres (log<sub>10</sub>) prior to a first booster inoculation at 42 days and at the final bleeds day  
 50 98. In terms of anti-HBsAg activity, good antibody levels were observed in final bleeds in rabbits and, particularly, in guinea pigs.

TABLE 1

Group 1	392 (2µg/ml)	HBcAg (2µg/ml)	PreS1-HBcAg (2µg/ml)
20µg 14	3.57	2.89	3.78
28	4.48	3.73	4.28
42	4.54	4.16	4.59
71*	4.63	3.87	3.79
77	5.39	4.20	4.44
84	4.69	4.24	4.46
98*	5.15	4.32	4.73
Group 2			
2µg 14	2.73	3.15	3.30
28*	4.20	3.69	3.57
42	4.22	3.39	3.39
71*	4.16	3.77	3.93
77	4.02	3.77	3.94
84	4.15	3.95	3.90
98*	4.60	4.41	4.31
ELISA end point titres log <sub>10</sub>			
* mean of group of individuals			

**Table 2: Response of guinea pigs to preS2 (QM2/PE3) cores**  
**(small epitope)**

**(a) 20µg dose**

Days post primary inoculation	peptide <u>393</u>	HBcAg	QM2 <u>cores</u>	HBsAg + <u>preS2</u>
0**	<1*	<1	<1	<1
14	2.5	2.2	3.3	2.1
28	3.2	3.0	4.1	3.1
42	3.6	3.3	4.2	3.4
70**	3.6	4.4	4.5	3.8
77	3.9	4.4	4.5	3.9
84	4.2	4.7	5.2	4.4
98	4.1	4.6	4.9	4.1



(b) 2µg dos

5	Drugs post primary	Test antigen		
	inoculation	peptide	HBcAg	QM2
			HBsAg	
10		<u>393</u>		<u>cores</u>
				<u>+preS2</u>
	0**	<1*	<1	<1
15	14	2.0	2.0	3.0
	28	2.1	2.6	3.5
	42	2.3	3.3	3.3
20	70**	2.5	3.7	3.7
	77	3.2	4.2	4.1
25	84	3.7	4.8	4.7
	98	3.4	4.6	4.9
				4.2

30

\* log<sub>10</sub> end point titre

\*\* inoculations

35

40

45

50

55

**Table 3: Comparative immunogenicity of "insert" and "terminal" HBcAg/HRV peptide fusion protein particles in guinea pigs**

(a) Anti-HRV peptide

Peptide dose ( $\mu$ g)	28 days post primary		56 days post primary		28 days post boost	
	insert	terminal	insert	terminal	insert	terminal
1.5	3.6*	2.7	4.1	2.9	4.8	3.6
0.15	2.5	1.3	3.1	2.3	4.3	2.9
0.015	1.9	<1.0	2.1	<1.0	3.5	<1.0

(b) Anti-HRV

Peptide dose ( $\mu$ g)	28 days post primary		56 days post primary		28 days post boost	
	insert	terminal	insert	terminal	insert	terminal
1.5	3.9*	1.6	4.2	1.5	5.1	2.8
0.15	2.3	1.2	2.5	1.6	4.2	2.5
0.015	1.6	1.2	1.8	1.0	3.5	1.0

\* ELISA endpoint titre ( $\log_{10}$ )

**Table 4: Comparative immunogenicity of "insert" and "terminal" HBcAg/HRV peptide fusion protein particles in rabbits**

5

(a) Anti-HRV peptide

Peptide dose ( $\mu$ g)	28 days post primary		56 days post primary		28 days post boost	
	insert	terminal	insert	terminal	insert	terminal
1.5	3.0*	2.2	3.2	2.4	4.2	2.9
0.15	2.7	1.5	2.4	1.5	3.1	1.7
0.015	2.1	N.D.	1.8	N.D.	2.7	N.D.

25

(b) Anti- HRV

Peptide dose ( $\mu$ g)	28 days post primary		56 days post primary		28 days post boost	
	insert	terminal	insert	terminal	insert	terminal
1.5	2.1*	1.2	2.5	1.1	4.0	1.4
0.15	1.8	1.1	2.0	1.1	2.8	1.5
0.015	1.7	N.D.	1.6	N.D.	2.4	N.D.

45

N.D. = not determined

\* ELISA endpoint titre ( $\log_{10}$ )

55

TABLE 5

(a) Guinea pigs	Neutralization titre
peptide dose ( $\mu$ g)	90% Plaque reduction
1.5	90, 30, 50, 25
0.15	20, 5
0.015	<5, <5
(b) Rabbits	Neutralization titre
peptide dose ( $\mu$ g)	90% Plaque reduction
1.5	300, 5
0.15	10, 15
0.015	<5, <5

TABLE 6

				1st Inoc.	2nd Inoc.
chimaeric HBsAg 139-147 HBcAg protein	Rabbits	20 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	3.3 1.6	3.4 2.7
		2 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	2.6 1.3	3.0 2.4
		0.2 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	2.7 1.2	3.2 1.4
	Guinea Pigs	20 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	3.9 3.6	5.1 5.0
		2 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	3.0 1.9	4.3 4.0
		0.2 $\mu$ g	$\alpha$ pep448 $\alpha$ HBsAg	2.1 <1	4.0 2.4

**Claims**

**Claims for the following Contracting States : BE, CH, DE, DK, FR, GB, IT, LI, NL, SE**

- Particles composed of a chimaeric hepadnavirus core antigen protein having a foreign amino acid sequence comprising an epitope inserted in or replacing all or part of the amino acid sequence from residue 75 to residue 85 in the case where the core antigen is hepatitis B core antigen (HBcAg) or the corresponding amino acid sequence in the case of the core antigen of another hepadnavirus.
- Particles according to claim 1, wherein the foreign amino acid sequence is up to 40 amino acid residues in length.
- Particles according to claim 2, wherein the foreign amino acid sequence is up to 20 amino acid residues in length.
- Particles according to any one of the preceding claims, wherein the foreign amino acid sequence is inserted between HBcAg residues 80 and 81 or between the corresponding residues of the core protein of another hepadnavirus.
- Particles according to any one of the preceding claims, wherein the epitope is the epitope of a pathogen.

6. Particles according to claim 5, wherein the epitope is an epitope of hepatitis A virus, hepatitis B virus, influenza virus, foot-and-mouth disease virus, poliovirus, herpes simplex virus, rabies virus, feline leukaemia virus, human immunodeficiency virus type 1 or 2, simian immunodeficiency virus, human rhinovirus, dengue virus or yellow fever virus.
7. Particles according to any one of the preceding claims, wherein a second said foreign amino acid sequence is fused to the N-terminus of the amino acid sequence of the core protein.
8. A vector which comprises a DNA sequence encoding a chimaeric protein as specified in any one of the preceding claims and which is capable, when provided in a suitable host, of expressing the chimaeric protein.
9. A host transformed with a vector according to claim 8 so that the chimaeric protein is able to be expressed therein.
10. A process for the preparation of particles as claimed in any one of claims 1 to 7, which process comprises culturing a host according to claim 9 under such conditions that the chimaeric protein is expressed therein and recovering particles composed of the chimaeric protein which thus form.
11. A process for the preparation of a host as claimed in claim 9, which process comprises transforming a host with a compatible expression vector according to claim 8.
12. An expression vector which comprises a DNA sequence encoding a hepadnavirus core antigen and having (a) a restriction site within the sequence encoding HBcAg amino acid residues 75 to 85 or the corresponding sequence of the core protein of another hepadnavirus or (b) two restriction sites flanking a said sequence or a part of a said sequence.
13. A vector according to claim 12, wherein the restriction site (a) occurs at HBcAg codons 80 and 81 or at the corresponding core protein codons of another hepadnavirus.
14. A vector according to claim 12, which is pPV-Nhe (as harboured in deposit NCIMB 40210).
15. A process for the preparation of a vector as claimed in claim 8 which process comprises:
  - (i) digesting with the appropriate restriction endonuclease(s) an expression vector as claimed in any one of claims 12 to 14 such as to cut the vector at restriction site (a) or restriction site (b);
  - (ii) dephosphorylating the digested vector; and
  - (iii) ligating a DNA sequence encoding a foreign amino acid sequence comprising an epitope into the vector.
16. A pharmaceutical or veterinary formulation comprising a pharmaceutically or veterinarily acceptable carrier or diluent and, as active ingredient, particles as claimed in any one of claims 1 to 7.

#### Claims for the following Contracting State : ES

1. A process for the preparation of particles composed of a chimaeric hepadnavirus core antigen protein having a foreign amino acid sequence comprising an epitope inserted in or replacing all or part of the amino acid sequence from residue 75 to residue 85 in the case where the core antigen is hepatitis B core antigen (HBcAg) or the corresponding amino acid sequence in the case of the core antigen of another hepadnavirus, which process comprises
  - (I) culturing a host transformed with a compatible expression vector which comprises a DNA sequence encoding a said chimaeric protein under such conditions that the chimaeric protein is expressed in the host, and
  - (II) recovering particles composed of the chimaeric protein which thus form.
2. A process according to claim 1, wherein the foreign amino acid sequence is up to 40 amino acid residues in length.

3. A process according to claim 2, wherein the foreign amino acid sequence is up to 20 amino acid residues in length.
4. A process according to any one of the preceding claims, wherein the foreign amino acid sequence is inserted between HBcAg residues 80 and 81 or between the corresponding residues of the core protein of another hepadnavirus.
5. A process according to any one of the preceding claims, wherein the epitope is the epitope of a pathogen.
6. A process according to claim 5, wherein the epitope is an epitope of hepatitis A virus, hepatitis B virus, influenza virus, foot-and-mouth disease virus, poliovirus, herpes simplex virus, rabies virus, feline leukaemia virus, human immunodeficiency virus type 1 or 2, simian immunodeficiency virus, human rhinovirus, dengue virus or yellow fever virus.
7. A process according to any one of the preceding claims, wherein a second said foreign amino acid sequence is fused to the N-terminus of the amino acid sequence of the core protein.
8. A process for the preparation of a transformed host which process comprises transforming a host with a compatible expression vector which comprises a DNA sequence encoding a chimaeric hepadnavirus core antigen protein as defined in any one of the preceding claims.
9. A process for the preparation of a vector which comprises a DNA sequence encoding a chimaeric hepadnavirus core antigen protein as defined in any one of claims 1 to 7 and which is capable, when provided in a suitable host, of expressing the chimaeric protein; which process comprises:
  - (i) digesting with the appropriate restriction endonuclease(s) an expression vector which comprises a DNA sequence encoding a hepadnavirus core antigen and having (a) a restriction site within the sequence encoding HBcAg amino acid residues 75 to 85 or the corresponding sequence of the core protein of another hepadnavirus or (b) two restriction sites flanking a said sequence or a part of a said sequence, such as to cut the vector at restriction site (a) or restriction site (b);
  - (ii) dephosphorylating the digested vector; and
  - (iii) ligating a DNA sequence encoding a foreign amino acid sequence comprising an epitope into the vector.
10. A process according to claim 9, wherein the restriction site (a) occurs at HBcAg codons 80 and 81 or at the corresponding core protein codons of another hepadnavirus.
11. A process according to claim 10, wherein the expression vector is pPV-Nhe (as harboured in deposit NCIMB 40210).

#### Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, DK, FR, GB, IT, LI, NL, SE

1. Teilchen bestehend aus chimärischem Hepadnavirus-Kernantigenprotein, das eine fremde Aminosäuresequenz hat, welche ein Epitop enthält, das in die Aminosäuresequenz zwischen Rest 75 und Rest 85 für den Fall, daß das Kernantigen Hepatitis B-Kernantigen (HBcAg) ist, oder in die entsprechende Aminosäuresequenz für den Fall, daß das Kernantigen von einem anderen Hepadnavirus ist, eingefügt ist oder diese ganz oder teilweise ersetzt.
2. Teilchen nach Anspruch 1, in denen die fremde Aminosäuresequenz eine Länge von bis zu 40 Aminosäureresten hat.
3. Teilchen nach Anspruch 2, in denen die fremde Aminosäuresequenz eine Länge von bis zu 20 Aminosäureresten hat.
4. Teilchen nach einem der vorangehenden Ansprüche, in denen die fremde Aminosäuresequenz zwischen die HBcAg-Reste 80 und 81 oder zwischen die entsprechenden Reste des Kernproteins eines anderen Hepadnavirus eingefügt ist.

5. Teilchen nach einem der vorangehenden Ansprüche, in denen das Epitop das Epitop eines Krankheitserregers ist.
6. Teilchen nach Anspruch 5, in denen das Epitop ein Epitop des Hepatitis A-Virus, Hepatitis B-Virus, Influenza-Virus, Virus der Maul- und Klauenseuche, Poliovirus, Herpes simplex-Virus, Tollwutvirus, Katzenleukämie-Virus, humanen Immundefizienzvirus Typ 1 oder 2, Affen-Immundefizienzvirus, humanen Rhinovirus, Dengue-Virus oder Gelbfieberevirus ist.
7. Teilchen nach einem der vorangehenden Ansprüche, in denen eine zweite fremde Aminosäuresequenz an das N-Ende der Aminosäuresequenz des Kernproteins kondensiert ist.
8. Vektor, der eine DNA-Sequenz enthält, die ein chimärisches Protein wie es in einem der vorangehenden Ansprüche spezifiziert ist, kodiert und der, wenn er in einem geeigneten Wirt bereitgestellt wird, das chimärische Protein exprimiert.
9. Wirt, der mit einem Vektor gemäß Anspruch 8 transformiert ist, so daß das chimärische Protein darin exprimiert werden kann.
10. Verfahren zur Herstellung von Teilchen, wie sie in einem der Ansprüche 1 bis 7 beansprucht sind; wobei das Verfahren Kultivieren eines Wirts nach Anspruch 9 unter solchen Bedingungen, daß das chimärische Protein darin exprimiert wird, und Isolieren von Teilchen, die aus dem auf diese Weise gebildeten chimärischen Protein bestehen, umfaßt.
11. Verfahren zur Herstellung eines Wirts nach Anspruch 9, wobei das Verfahren ein Transformieren eines Wirts mit einem verträglichen Expressionsvektor nach Anspruch 8 umfaßt.
12. Expressionsvektor, der eine DNA-Sequenz enthält, welche ein Hepadnavirus-Kernantigen kodiert und (a) eine Restriktionsstelle innerhalb der Sequenz, die die HBcAg-Aminosäurereste 75 bis 85 oder die entsprechende Sequenz des Kernproteins eines anderen Hepadnavirus kodiert, oder (b) zwei Restriktionsstellen hat, die diese Sequenz oder einen Teil dieser Sequenz flankieren.
13. Vektor nach Anspruch 12, in dem die Restriktionsstelle (a) an den HBcAg-Kodons 80 und 81 oder an den entsprechenden Kernprotein-Kodons eines anderen Hepadnavirus auftritt.
14. Vektor nach Anspruch 12, der pPV-Nhe (wie in der Hinterlegung NCJMB 40210 verborgen) ist.
15. Verfahren zur Herstellung eines Vektors, wie er in Anspruch 8 beansprucht ist, wobei das Verfahren (i) Aufschließen eines Expressionsvektors, wie er in einem der Ansprüche 12 bis 14 beansprucht ist, mit der geeigneten Restriktions-Endonuclease (geeigneten Endonucleasen) derart, daß der Vektor an Restriktionsstelle (a) oder Restriktionsstelle (b) geschnitten wird; (ii) Dephosphorylierung des aufgeschlossenen Vektors; (iii) Binden einer DNA-Sequenz, die eine fremde Aminosäuresequenz, welche ein Epitop enthält, kodiert, an den Vektor.
16. Pharmazeutische oder tiermedizinische Formulierung, die einen pharmazeutisch oder tiermedizinisch akzeptablen Trägerstoff oder ein pharmazeutisch oder tiermedizinisch akzeptables Verdünnungsmittel und als aktives Ingrediens Teilchen, wie sie in einem der Ansprüche 1 bis 7 beansprucht sind, enthält.

**Patentansprüche für folgenden Vertragsstaat : ES**

1. Verfahren zur Herstellung von Teilchen bestehend aus chimärischem Hepadnavirus-Kernantigenprotein, das eine fremde Aminosäuresequenz hat, welche ein Epitop enthält, das in die Aminosäuresequenz zwischen Rest 75 und Rest 85 für den Fall, daß das Kernantigen Hepatitis B-Kernantigen (HBcAg) ist, oder in die entsprechende Aminosäuresequenz für den Fall, daß das Kernantigen von einem anderen Hepadnavirus ist, eingefügt ist oder diese ganz oder teilweise ersetzt, wobei das Verfahren (i) Kultivieren eines Wirts, der mit einem verträglichen Expressionsvektor, welcher eine DNA-Sequenz enthält, die das chimärische Protein kodiert, transformiert ist, unter solchen Bedingungen, daß das chimärische Prot in in dem Wirt exprimiert wird; und

(II) Isolieren von Teilchen, die aus dem auf diese Weise gebildeten chimärischen Protein bestehen, umfaßt.

2. Verfahren nach Anspruch 1, in denen die fremde Aminosäuresequenz eine Länge von bis zu 40 Aminosäureresten hat.
3. Verfahren nach Anspruch 2, in denen die fremde Aminosäuresequenz eine Länge von bis zu 20 Aminosäureresten hat.
4. Verfahren nach einem der vorangehenden Ansprüche, in denen die fremde Aminosäuresequenz zwischen die HBcAg-Reste 80 und 81 oder zwischen die entsprechenden Reste des Kernproteins eines anderen Hepadnavirus eingefügt ist.
5. Verfahren nach einem der vorangehenden Ansprüche, in denen das Epitop das Epitop eines Krankheitserregers ist.
6. Verfahren nach Anspruch 5, in denen das Epitop ein Epitop des Hepatitis A-Virus, Hepatitis B-Virus, Influenza-Virus, Virus der Maul- und Klauenseuche, Poliovirus, Herpes simplex-Virus, Tollwutvirus, Katzenleukämie-Virus, humanen Immundefizienzvirus Typ 1 oder 2, Affen-Immundefizienzvirus, humanen Rhinovirus, Dengue-Virus oder Gelbfieberevirus ist.
7. Verfahren nach einem der vorangehenden Ansprüche, in denen eine zweite fremde Aminosäuresequenz an das N-Ende der Aminosäuresequenz des Kernproteins kondensiert ist.
8. Verfahren zur Herstellung eines transformierten Wirts, das Transformieren eines Wirts mit einem verträglichen Expressionsvektor, der eine DNA-Sequenz enthält, die ein chimärisches Hepadnavirus-Kernantigen, wie es in einem der vorangehenden Ansprüche definiert ist, kodiert, umfaßt.
9. Verfahren zur Herstellung eines Vektors, der eine DNA-Sequenz enthält, die ein chimärisches Hepadnavirus-Kernantigenprotein, wie es in einem der Ansprüche 1 bis 7 definiert ist, kodiert, und der, wenn er in einem geeigneten Wirt angesiedelt wird, das chimärische Protein exprimieren kann;
  - (i) Aufschließen eines Expressionsvektors, der eine DNA-Sequenz enthält, die ein Hepadnavirus-Kernantigen kodiert und die eine Restriktionsstelle (a) in der Sequenz, die die HBcAg-Aminosäurereste 75 bis 85 oder die entsprechende Sequenz des Kernproteins eines anderen Hepadnavirus kodiert, oder (b) zwei Restriktionsstellen hat, die diese Sequenz oder einen Teil dieser Sequenz flankieren, hat, derart, daß der Vektor an Restriktionsstelle (a) oder Restriktionsstelle (b) geschnitten wird;
  - (ii) Dephosphorylierung des aufgeschlossenen Vektors; und
  - (iii) Binden einer DNA-Sequenz, die eine fremde Aminosäuresequenz, welche ein Epitop enthält, kodiert, im Vektor.
10. Verfahren nach Anspruch 9, in dem die Restriktionsstelle (a) an den HBcAg-Kodons 80 und 81 oder an den entsprechenden Kernprotein-Kodons eines anderen Hepadnavirus auftritt.
11. Verfahren nach Anspruch 10, in dem der Expressionsvektor pPV-Nhe (wie in der Hinterlegung NCJMB 40210 verborgen ist) ist.

#### Revendications

Revendications pour les Etats contractants suivants : BE, CH, DE, DK, FR, GB, IT, LI, NL, SE

1. Particules composées d'une protéine chimérique d'antigène de core d'un hepadnavirus ayant une séquence d'acides aminés étrangère comprenant un épitope inséré dans ou remplaçant la totalité ou une partie de la séquence d'acides aminés du résidu 75 au résidu 85 dans le cas où l'antigène de core est l'antigène de core de l'hépatite B (HBcAg) ou la séquence d'acides aminés correspondante dans le cas de l'antigène de core d'un autre hepadnavirus.
2. Particules selon la revendication 1, dans lesquelles la séquence d'acides aminés étrangère comporte jusqu'à 40 résidus d'acides aminés.



3. Particules selon la revendication 2, dans lesquelles la séquence d'acides aminés étrangère comporte jusqu'à 20 résidus d'acides aminés.
4. Particules selon l'une quelconque des revendications précédentes, dans lesquelles la séquence d'acides aminés étrangère est insérée entre les résidus 80 et 81 de HBcAg ou entre les résidus correspondants de la protéine de core d'un autre hepadnavirus.
5. Particules selon l'une quelconque des revendications précédentes, dans lesquelles l'épitope est l'épitope d'un pathogène.
6. Particules selon la revendication 5, dans lesquelles l'épitope est un épitope du virus de l'hépatite A, du virus de l'hépatite B, du virus de la grippe, du virus de la fièvre aphteuse, du poliovirus, de l'herpès simplex virus, du virus de la rage, du virus de la leucémie du chat, du virus de l'immunodéficience humaine de type 1 ou 2, du virus de l'immunodéficience du singe, du rhinovirus humain, du virus de la dengue ou du virus de la fièvre jaune.
7. Particules selon l'une quelconque des revendications précédentes, dans lesquelles une seconde séquence d'acides aminés étrangère telle que mentionnée est fusionnée à la partie N-terminale de la séquence d'acides aminés de la protéine de core.
8. Vecteur qui comprend une séquence d'ADN codant pour une protéine chimérique telle que spécifiée dans l'une quelconque des revendications précédentes et qui est capable, lorsqu'il est introduit dans un hôte approprié, d'exprimer la protéine chimérique.
9. Hôte transformé avec un vecteur selon la revendication 8, de sorte que la protéine chimérique puisse être exprimée dans celui-ci.
10. Procédé de préparation des particules telles que revendiquées dans l'une quelconque des revendications 1 à 7, procédé qui comprend les étapes consistant à cultiver un hôte selon la revendication 9 dans des conditions telles que la protéine chimérique soit exprimée dans celui-ci, et à récupérer les particules composées de la protéine chimérique qui sont ainsi formées.
11. Procédé de préparation d'un hôte tel que revendiqué à la revendication 9, procédé qui comprend la transformation d'un hôte avec un vecteur d'expression compatible selon la revendication 8.
12. Vecteur d'expression qui comprend une séquence d'ADN codant pour un antigène de core d'un hepadnavirus et ayant (a) un site de restriction dans la séquence codant pour les résidus d'acides aminés 75 à 85 de HBcAg ou la séquence correspondante de la protéine de core d'un autre hepadnavirus ou (b) deux sites de restriction flanquant une séquence telle que mentionnée ou une partie d'une séquence telle que mentionnée.
13. Vecteur selon la revendication 12, dans lequel le site de restriction (a) est situé aux codons 80 et 81 de HBcAg ou aux codons correspondants de la protéine de core d'un autre hepadnavirus.
14. Vecteur selon la revendication 12, qui est pPV-Nhe (tel que contenu dans le dépôt NCIMB 40210).
15. Procédé de préparation d'un vecteur tel que revendiqué à la revendication 8, procédé qui comprend les étapes consistant à :
  - (i) digérer avec la (les) endonucléase(s) de restriction appropriée(s) un vecteur d'expression tel que revendiqué dans l'une quelconque des revendications 12 à 14, de façon à couper le vecteur au site de restriction (a) ou au site de restriction (b);
  - (ii) déphosphoryler le vecteur digéré; et
  - (iii) ligaturer dans le vecteur une séquence d'ADN codant pour une séquence d'acides aminés étrangère comprenant un épitope.
16. Formulation pharmaceutique ou vétérinaire comprenant un véhicule ou un diluant acceptable d'un point de vue pharmaceutique ou vétérinaire et, comme ingrédient actif, des particules telles que revendiquées dans l'une quelconque des revendications 1 à 7.

Revendications pour l'Etat contractant suivant : ES

1. Procédé de préparation de particules composées d'une protéine chimérique d'antigène de core d'un  
 5 hepadnavirus ayant une séquence d'acides aminés étrangère comprenant un épitope inséré dans ou remplaçant la totalité ou une partie de la séquence d'acides aminés du résidu 75 au résidu 85 dans le cas où l'antigène de core est l'antigène de core de l'hépatite B (HBcAg) ou la séquence d'acides aminés correspondante dans le cas de l'antigène de core d'un autre hepadnavirus, procédé qui comprend les étapes consistant à  
 (I) cultiver un hôte transformé avec un vecteur d'expression compatible qui comprend une séquence  
 10 d'ADN codant pour une protéine chimérique telle que mentionnée dans des conditions telles que la protéine chimérique soit exprimée dans l'hôte, et  
 (II) récupérer les particules composées de protéine chimérique qui sont ainsi formées.
2. Procédé selon la revendication 1, dans lequel la séquence d'acides aminés étrangère comporte jusqu'à  
 15 40 résidus d'acides aminés.
3. Procédé selon la revendication 2, dans lequel la séquence d'acides aminés étrangère comporte jusqu'à 20 résidus d'acides aminés.
- 20 4. Procédé selon l'une quelconque des revendications précédentes, dans lequel la séquence d'acides aminés étrangère est insérée entre les résidus 80 et 81 de HBcAg ou entre les résidus correspondants de la protéine de core d'un autre hepadnavirus.
5. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'épitope est l'épitope  
 25 d'un pathogène.
6. Procédé selon la revendication 5, dans lequel l'épitope est un épitope du virus de l'hépatite A, du virus de l'hépatite B, du virus de la grippe, du virus de la fièvre aphteuse, du poliovirus, de l'herpès simplex virus, du virus de la rage, du virus de la leucémie du chat, du virus de l'immunodéficience humaine de  
 30 type 1 ou 2, du virus de l'immunodéficience du singe, du rhinovirus humain, du virus de la dengue ou du virus de la fièvre jaune.
7. Procédé selon l'une quelconque des revendications précédentes, dans lequel une seconde séquence d'acides aminés étrangère telle que mentionnée est fusionnée à la partie N-terminale de la séquence  
 35 d'acides aminés de la protéine de core.
8. Procédé de préparation d'un hôte transformé, procédé qui comprend la transformation d'un hôte avec un vecteur d'expression compatible qui comprend une séquence d'ADN codant pour une protéine chimérique d'antigène de core d'un hepadnavirus, tel que défini dans l'une quelconque des revendica-  
 40 tions précédentes.
9. Procédé de préparation d'un vecteur qui comprend une séquence d'ADN codant pour une protéine chimérique d'antigène de core d'un hepadnavirus tel que défini dans l'une quelconque des revendica-  
 45 tions 1 à 7 et qui est capable, lorsqu'il est fourni à un hôte approprié, d'exprimer la protéine chimérique; procédé qui comprend les étapes consistant à :  
 (i) digérer avec la (les) endonucléase(s) de restriction appropriée(s) un vecteur d'expression qui comprend une séquence d'ADN codant pour un antigène de core d'un hepadnavirus et ayant (a) un site de restriction dans la séquence codant pour les résidus d'acides aminés 75 à 85 de HBcAg ou la séquence correspondante de la protéine de core d'un autre hepadnavirus ou (b) deux sites de  
 50 restriction flanquant une séquence telle que mentionnée ou une partie d'une séquence telle que mentionnée, de façon à couper le vecteur au site de restriction (a) ou au site de restriction (b) ;  
 (ii) déphosphoryler le vecteur digéré; et  
 (iii) ligaturer dans le vecteur une séquence d'ADN codant pour une séquence d'acides aminés étrangère comprenant un épitope.  
 55
10. Procédé selon la revendication 9, dans lequel le site de restriction (a) est situé aux codons 80 et 81 de HBcAg ou aux codons correspondants de la protéine de core d'un autre hepadnavirus.

**11. Procédé selon la revendication 10, dans lequel le vecteur d'expression est pPV-Nhe (tel que contenu dans le dépôt NCIMB 40210).**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**